Evidence map›Paper›PMID 32969027›Full record

ArticleThe British journal of dermatology2021

Hidradenitis Suppurativa Area and Severity Index Revised (HASI-R): psychometric property assessment.

N Goldfarb, M A Lowes, M Butt, T King, A Alavi, J S Kirby

Abstract read
In one paragraph

Article in The British journal of dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025
    Guideline
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

N GoldfarbDepartments of Medicine and Dermatology, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0003-1070-0652
M A LowesThe Rockefeller University, New York, NY, USA.
M ButtDepartment of Dermatology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.ORCID 0000-0002-5860-1074
T KingDepartment of Dermatology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
A AlaviDepartment of Medicine, Division of Dermatology, Women's College Hospital, University of Toronto, Toronto, Canada.ORCID 0000-0003-1171-4917
J S KirbyDepartment of Dermatology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.

Funding

Penn State Clinical and Translational Science InstituteUL1TR002014 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI KRASCHNEWSKI, JENNIFER L. · 2016 to 2025
$33.7M
Penn State Clinical and Translational Science InstituteUL1TR000127 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SINOWAY, LAWRENCE I · 2012 to 2015
$17.1M
Development of Outcome Measures for Hidradenitis SuppurativaK08HS024585 · AHRQ · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI KIRBY, JOSLYN S · 2016 to 2019
$633k
AHRQ HHS K08 HS024585International Dermatology Outcome Measures InitiativeNCATS NIH HHS UL1 TR000127NCATS NIH HHS UL1 TR002014
6 · The paper itself

Abstract

backgroundValidated, reliable, globally accepted outcome measurement instruments for hidradenitis suppurativa (HS) are needed. Current tools to measure the physical signs domain for HS rely on lesion counts, which are time-consuming and unreliable.

objectivesTo assess the reliability and validity of the Hidradenitis suppurativa Area and Severity Index Revised (HASI-R) tool, a novel method for assessing HS severity, incorporating signs of inflammation and body surface area involved.

methodsThe measurement properties of the HASI-R tool were evaluated. The tool was created by combining the previously published HASI and Severity and Area Score for Hidradenitis instruments. Twenty raters evaluated 15 patients with HS in a hospital-based ambulatory dermatology clinic. The objectives of the study were to assess inter- and intra-rater reliability of the HASI-R and its components, as well as its construct and known-groups validity. Existing lesion count-based clinician-reported measures of HS and their components were also assessed. Raters were also asked their preferences regarding the various HS severity assessment tools.

resultsThe HASI-R had moderate inter-rater reliability [intra-class correlation coefficients (ICC) 0·60]. This was better than all other HS physical sign outcome measures evaluated, which had poor inter-rater reliability (ICC < 0·5). HASI-R had the highest intra-rater reliability (ICC 0·91). The HASI-R had good construct validity and demonstrated known-groups validity. The HASI-R was also the most preferred tool by all raters.

conclusionsResults from the clinometric assessment of the HASI-R are encouraging, and support continued evaluation of this clinician-reported outcome measure.

Indexed as

Hidradenitis SuppurativaHumansPsychometricsReproducibility of ResultsSeverity of Illness Index

Identifiers

PMID32969027
PMCPMC8573730

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.